Browse News
Filter News
Found 115 articles
-
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
4/17/2024
Evaxion Biotech A/S announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
-
Computational Biology Market Size to Increase USD 21.04 Bn by 2033
4/12/2024
According to Nova One Advisor, the global computational biology market size was valued at USD 6.10 billion in 2023 and is projected to reach USD 21.04 billion by 2033, registering a CAGR of 13.18% from 2024 to 2033.
-
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
4/2/2024
Evaxion Biotech A/S is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus.
-
Evaxion Announces Business Update and Full Year 2023 Financial Results
3/27/2024
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
-
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
3/19/2024
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.
-
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
2/29/2024
Evaxion Biotech A/S announces that it will host a Research & Development Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.
-
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
2/20/2024
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).
-
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
2/7/2024
Evaxion Biotech A/S announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550.
-
Evaxion Announces Closing of $15 Million Public Offering
2/6/2024
Evaxion Biotech A/S today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares.
-
Evaxion Biotech Announces Pricing of $15 Million Public Offering
2/1/2024
Evaxion Biotech A/S announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS and accompanying warrant.
-
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
1/24/2024
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company") announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).
-
Evaxion Announces Completion of ADS Ratio Change
1/22/2024
Evaxion Biotech A/S announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares to its ordinary shares, DKK 1 nominal value, has been made effective.
-
Evaxion Announces Plan to Implement ADS Ratio Change
1/8/2024
Evaxion Biotech A/S announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares, DKK 1 nominal value, from the current one ADS representing one ordinary share to a new ADS Ratio of one ADS representing ten ordinary shares.
-
Evaxion Biotech Announces Closing of Private Placement - December 21, 2023
12/21/2023
Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announced the closing of its previously announced private placement with a gross proceed of $5.3 million.
-
Evaxion Biotech Announces Private Placement Financing
12/19/2023
Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce a private placement financing to raise gross proceeds of approximately $5.3 million.
-
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
12/19/2023
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
-
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
11/28/2023
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.
-
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
11/15/2023
Evaxion Biotech A/S presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.
-
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
11/6/2023
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak.
-
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
10/31/2023
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings.